Introduction
Tubular epithelial cells often suffer injury and damage caused by different factors such as ischaemia or toxicity (for review, see [1, 2] ). From the observations in human studies and animal models, it is clear that these acute insults can result in chronic kidney disease [3] . The structural and functional restoration of the kidney depends on a delicate balance of growth and transcription factors that guide gene expression [4] . The signalling pathways triggered during this process often resemble those observed during kidney development.
Tissue regeneration comprises dedifferentiation, proliferation and transdifferentiation processes [5] . After injury, surviving cells suffer dedifferentiation assuming progenitor cell characteristics (epithelial-to-mesenchymal transition) [6] . Indeed, markers of undifferentiated cells are reexpressed such as vimentin, which occurs in mesenchymal cells and not in mature cells [7] , and neural cell adhesion molecules expressed initially in the metanephric mesenchyme [8] . Many genes are reactivated during renal repair, such as c-Jun, c-Fos, c-Myc and EGR-1, leading these cells to resemble kidney organogenesis behaviour [9] . It is important to mention that not all genes involved in tissue repair are related to those activated during embryogenesis and vice-versa. These undifferentiated cells present a higher proliferation rate than that from normal adult kidney cells [10] . Data shown by Witzgall and coworkers [7] revealed that irreversible injured cells (expressing clusterin) do not express vimentin or proliferation cell nuclear antigen (PCNA), which are markers of undifferentiated and proliferating cells, respectively, supporting the idea that only surviving cells are capable of dedifferentiation and proliferation giving rise to cells that subsequently will suffer transdifferentiation. The new cells undergo mesenchymalto-epithelial differentiation functionally replacing the cells lost during injury. It seems to be a promising issue to explore these genes and transcriptional factors that are selectively expressed during embryogenesis and potentially re-expressed after tissue injury and thereby possibly modulate and enhance the regeneration process.
Despite the well-established importance of growth factors in kidney organogenesis and regeneration [11, 12] , there is much to investigate about the downstream effector pathways they regulate. Transcription factors activated by these pathways may be interesting targets for regenerative treatment strategies, especially because some of them are tissue specific. In this review, we focused on Pax-2, an important transcription factor that regulates transition of mesenchymal cells to an epithelial phenotype, expressed in the kidney during development [13] and re-expressed after injury [6, 14] .
Here we resume the relationship between the transcription factor Pax-2 and renal recovery process after injury, and discuss the mechanisms related to the regulation of its expression.
PAX Family
The PAX (paired homeobox) gene family plays a critical role during embryogenesis, encoding transcription factors that bind to DNA and regulate the expression of specific genes during development [14] [15] [16] [17] . The PAX family is classified into four groups according to their structural similarity, sequence homology, the presence or absence of an octapeptide motif and also according to its homeodomain or partial homeodomain [18] .
Pax proteins are characterized by the presence of a 128 amino acid sequence in their structure, which constitutes a DNA-binding domain, the paired domain (PD) [19] . Each Pax protein has a c-terminal region rich in serine and threonine that is responsible for transcriptional activation of target genes [19, 20] . These proteins can modulate the expression of diverse genes in a complex pattern, as it is mediated not only by the binding of PD to DNA but also through interactions with other DNA-binding domains, or even interactions with other PDs of Pax proteins [18] . The nine Pax genes (Pax-1 to Pax-9), described in humans and mice, are associated with organogenesis and maintenance of the pluripotency state of stem cell populations during development [19] . Each of them is tissue specific, and Pax-2 is responsible for eye, ear, central nervous system and urogenital tract development. Another member of Pax superfamily expressed during kidney development is Pax-8 [19, 21] , whereas it is not re-expressed during injury repair. For that reason, we will not quote this member of Pax family throughout the review.
PAX-2 in kidney development and repair
During embryogenesis, Pax-2 is detected in the caudal mesonephric duct, ureteric bud and later in mesenchymal condensates induced by the ureteric bud [22, 23] . In the final stages of kidney development, Pax-2 is restricted to the distal part of the S-shaped body and its expression disappears as the tubular epithelial cells differentiate [19] . Despite PAX-2 transient expression during embryogenesis, its deregulation is associated with several anomalies in mice and humans. Failure in PAX-2 expression leads to anephric kidneys, while its continued expression results in kidney malformations [24, 25] . Therefore, the correct upand downregulation of this gene are extremely important. Pax-2 binds to target sequences containing a core DNA sequence motif, GTTCC [26] and a 17 bp consensus binding site [27] . The transcription of PAX-2 can generate, by alternative splicing, three different transcription factors PAX2a, PAX2b and PAX2c, showing a more complex mechanism of regulation by this gene. It is difficult to list all the Pax-2-regulated genes, as the specifically Pax-2 binding domain seems to be virtually present in many different genes, and some of them not yet related to modulation by Pax-2. Table 1 shows a concise list of Pax-2-regulated genes already reported in kidney development [28] [29] [30] [31] [32] [33] [34] [35] . However, there are no reports, as far as we know, about specifically Pax-2-regulated genes during kidney repair. To date, the genes regulated by PAX-2 are Wilms' tumour suppressor gene WT1 [28] and Glial cell-derived neurotrophic factor (GDNF) [32] genes expressed in the metanephric mesenchyme and necessary for metanephron induction and growth; Gata3, required for morphogenesis and guidance of the nephric duct along the anteroposterior axis of the embryo [31] ; and other genes such as N-myc and p53 [30, 35] . Some of these genes (Nmyc and WT1) regulate the expression of PAX-2 through feedback mechanisms (see Figure 1) . The supposition that PAX-2 might play a crucial role in renal regeneration was reinforced after Imgrund and coworkers demonstrated that the PAX-2 gene was re-expressed in proximal tubule cells after injury [6] . In healthy adult kidneys, Pax-2 is detectable only in cells of the collecting ducts [36] . Later, Maeshima and coworkers using an ischaemia/reperfusion animal model confirmed that Pax-2 is singularly re-expressed among other transcription factors, like Pax-8, WT1, WnT4 and BF-2, also present during development [37] . These studies emphasize that the presence of Pax-2 may potentially influence renal regeneration, conducting key events as it does during development, but the actions of Pax-2 in renal recovery are still not well understood. Rothenpieler and Dressler in 1993 confirmed the hypothesis that Pax-2 was associated with mesenchymal-to-epithelial transformation, showing that the gene was actually required at the earliest phase of the kidney cell differentiation [13] . Yet, Maeshima and coworkers [37] pointed to modulation of cell proliferation and differentiation. They showed that the peak of Pax-2 expression preceded the peak for bromodeoxyuridine (BrdU)-positive cells in 6 h, that Pax-2 positive cells colocalized BrdU-positive cells and that using a Pax-2 inhibitor the proliferation rate decreased. So, PAX-2 expression would drive tubular kidney cells to proliferate. In addition, the expression of this gene has also been demonstrated to prevent apoptosis. Zhang and coworkers in 2004, using IRPTC (immortalized renal proximal tubular cells) transfected with PAX-2 sense and antisense transformants, showed that cells lacking PAX-2 gene expression are 2.4-fold more prone to enter apoptosis than control (IRPTC not transfected cells) and that their proliferation rate decreased by 50% [38] . Torban and coworkers [36] using different strategies, in vivo and in vitro, confirmed that the primary function of Pax-2 is preventing apoptosis, but demonstrated that Pax-2 does not lead to proliferation. Most of the literature is in agreement with the view that this gene protects cells from apoptosis; otherwise further studies are necessary to better clarify other features for Pax-2 actions in cell biology. Nevertheless, Maeshima and coworkers [39] evaluated the outcomes of cell cultures upon addition of activin A, a downregulator of PAX-2 expression, and follistatin, a protein that binds to activin preventing its connection to the receptor [40] . Those authors elegantly showed that in the absence of activin A cells of the ureteric bud undergo more proliferation and increase its branching. On the other hand, cells of the metanephric mesenchyme undergo more proliferation in the presence of activin A, while follistatin led these cells to apoptosis [39] , suggesting different actions for Pax-2 depending on the cell type or the microenvironment. The data mentioned above were obtained in in vitro experiments where it is noteworthy that Pax-2 is involved in cellular processes that play key roles during embryogenesis and kidney repair. There are very few in vivo approaches to directly associate Pax-2 with renal recovery after injury, especially showing the participation of Pax-2 in key processes related to tissue repair in vivo. It can be considered a growing field of interest as judged by the increasing number of studies showing that different factors known to influence renal tissue regeneration are now being related to PAX-2 gene expression [37, 38] .
PAX-2 upregulation: the renin-angiotensin system (RAS)
In spite of epidermal growth factor (EGF) being the first described positive modulator of PAX-2, its action relies on suppressing the degradation of the protein (Figure 1) . Thereby, EGF augment Pax-2 half-life within the cells with no direct action on PAX-2 expression [41, 42] .
Further reports associated the RAS with Pax-2 upregulation. Angiotensin II (ANG II) is among the most studied molecules in renal disease, classically acting through angiotensin II type 1 receptor (AT 1 R) and angiotensin II type 2 receptor (AT 2 R) [43, 44] . Similarities of kidney and urinary tract congenital abnormalities, when AT 2 R or PAX-2 genes were mutated during renal development, suggested that there might be a connection between them [45, 46] . AT 2 R and PAX-2 also share features like its transitory expression during renal development, absence or very low expression in the majority of adult renal cells and reexpression following injury [6, 47] . These clues prompted investigations about their interaction and led to the discovery that ANG II signalling via AT 2 R increases Pax-2 expression. Zhang and coworkers first demonstrated in vitro, using fetal renal explants, that ANG II enhanced expression of PAX-2 gene via AT 2 R and that Pax-2 reduced apoptosis and increased the proliferation rate of these cells [48] . Thereafter, in order to test Pax-2 and ANG II interaction in renal adult cells, IRPTC cultures were used and confirmed an association between AT 2 R and Pax-2 in adult renal injured cells acting toward renal protection [38] . According to their results, Pax-2 and AT 2 R have an anti-apoptotic effect after injury, just like during embryogenesis. In contradiction the expression of AT 2 R, in adult renal cells, is usually related to apoptosis induction and proliferation impairment [49, 50] . Moreover, the upregulation of Pax-2 via AT 2 R seems to be triggered through a JAK 2 /STAT-dependent pathway (Figure 1) , which was clearly demonstrated by Zhang and coworkers [38, 48] by using AG490 (a specific JAK 2 inhibitor). Yet, the pathways triggered by AT 2 R that lead to proliferation impairment and apoptosis involve the activation of protein phosphatases [43] .
The functions of AT 1 R are well established, while the precise role of AT 2 R in adult kidney remains to be determined [51] . Among the different effects ascribed to ANG II through the activation of AT 2 R in renal tissue, many reports show controversial data, principally triggering either an apoptotic or an anti-apoptotic pathway [52, 53] . Moreover, it has been reported that cells may simultaneously undergo both proliferative and apoptotic routes in a broad range of pathophysiological situations [51] . In this context, proliferative and apoptotic responses to tissue injury may share common cell cycle pathways, thus supporting the view that these processes are closely related in disease states, here included renal injuries [54] .
We hypothesized the possibility that the signalling route of AT 2 R can interact with some other factor responsible for triggering the apoptotic or antiapoptotic destiny of the AT 2 R cascade. More research is necessary to confirm this hypothesis and verify interaction of AT 2 R and Pax-2 in those cases that an apoptotic answer to the AT 2 R signalling was obtained.
PAX-2 downregulation: activin A
Activins are multifunctional cytokines that belong to transforming growth factor (TGF)-β superfamily [55] , which are expressed in different organs [56] . In kidneys, they are expressed during development and re-expressed after injury periods [57, 58] . These proteins act as autocrine factors and play different roles in kidney such as activation of renal interstitial fibroblasts [59] , inhibition of cell growth, promotion of differentiation and apoptosis in renal tubular cells, playing a key role in tissue regeneration [55, 60] .
The putative mechanism of action of activin A is regulation of the expression of transcription factors like Pax-2 [61] . Data presented by Maeshima and coworkers showed that Pax-2-positive cells present specific activin A receptors (ActR-II) and that administration of activin A leads to reduction of the number of cells BrdU/Pax-2 double positive in vivo [37] . In addition, activin A leads to reduction of PAX-2 expression in the kidney culture system during embryonic development as well as in tubular cell lineages [37, 55, 62] . The inhibition of activin A, either by follistatin or by superexpression of a mutant truncated receptor, leads to increases in PAX-2 expression and cell growth promotion [37] .
The action of activin A is mediated by two types of receptors present in an oligomeric form: type I (ActR-I) and type II (ActR-II) that have a serine/threonine kinase intracellular domain [65] . Activin A initially binds to ActR-II, present at the cellular membrane, activating the kinase intracellular domain, which recruits the ActR-I receptor, activating this receptor through phosphorylation of a glycine-rich domain and serine residues, forming a heteromeric receptor complex. After ActR-I activation, Smad-2 or Smad-3 are phosphorylated by the heteromeric complex, starting intracellular signalling events. Smad-4 then binds to the phosphorylated Smad forming a complex that is translocated into the nucleus and regulates transcription of target genes [64, 65] , in this case the PAX-2 gene (Figure 1 ).
Recent studies have demonstrated the existence of Smadindependent pathways. Transcription factor ATF2 and p38 are also activated through binding of activin A within its receptors [66] . This activation is mediated by transforming growth factor-β-activated kinase (TAK1) ( [67] , see Figure 1 ). The addition of activin A with specific inhibitors for p38 kinase to these cells showed similar cellular growth rates to that from the control group, configuring inhibition of activin A effect through this pathway. Furthermore, these inhibitors did not affect phosphorylation of Smad-2, showing that this Smad-independent pathway has an essential role in growth regulation through activin A. This result suggests a synergistic effect between these pathways: by Smad and p38 MAPK, or an interaction between Smad and ATF2 (Figure 1 ). Another study showed also a Smadindependent signalling pathway but through activation of RhoA and consequently phosphorylation of JNK and transcription factor c-Jun by MEKK1 [68] .
Another member of TGF-β superfamily has been related to the regulation of Pax-2-the TGF-β1. This growth factor is related to important biological processes such as apoptosis, cell growth, tissue regeneration and development [69] . TGF-β1 expression is rapidly enhanced in damaged and regenerating proximal tubules where it plays a role in tubular cell proliferation, tubulogenesis and apoptosis [70] . More than a decade ago, Liu and coworkers demonstrated that TGF-β1 promotes a negative regulation in the expression of the Pax-2 protein [41] . However, differently from activin A, TGF-β1 downregulates PAX-2 gene expression through a posttranscriptional process [41] . This mechanism, known for modulating important growth regulatory gene products, affects the stability of PAX-2 mRNA and consequently promotes a reduction of the Pax-2 protein in the cell.
In this sense, activin A and TGF-β1 are important mediators in renal repair responses. These growth factors promote downregulation of PAX-2 expression inhibiting cellular proliferation, which are essential mechanisms to counterbalance the promitogenic activity initiated by EGF and ANG II, preventing a disorderly cellular proliferation in renal regeneration.
Future Perspectives
The observation that Pax-2 plays an important role in renal recovery after injury led us to put together the literature about Pax-2 and Pax-2-regulated genes in order to emphasize its potential role for future combined therapy strategies towards kidney repair. The mechanisms involved in the regulation of the PAX-2 gene are beginning to be delineated. The view that ANG II upregulates Pax-2 expression through AT 2 R points to an interesting perspective that arises from a natural phenomenon observed after kidney injury, the overexpression of AT 2 R accompanied by re-expression of the Pax-2 gene in the adult kidney. These events would stimulate the remaining cells to proliferate and decrease their rate of apoptosis, giving support to restoration of damaged tubules. Therefore, the development of new selective AT 2 R agonists combined to specific AT 1 R inhibitors might represent a potential tool to selectively trigger repair process in the damaged kidney. The growing list of endogenous factors involved in the Pax-2 signalling pathway adds new approaches towards the development of alternative therapies for complete kidney repair after different insults.
As continued cell proliferation would be harmful to the tissue, downregulation mechanism for the PAX-2 gene is also of great interest. In this case, activin A, shown to be selectively expressed during embryogenesis, acts through binding to specific receptors triggering intracellular cascades that culminate with downregulation of the PAX-2 gene, controlling the rate of cell proliferation and promoting mesenchymal-to-epithelial transition. This process would not only guarantee recovery of tissue integrity by increasing the cell number but also provide a basis for kidney functional recovery by newly formed tubular epithelial cells.
